Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products

por Simpson, Mindy L., Desai, Vidhi, Maro, Géraldine S., Yan, Songkai
Publicado 2020

The Authors Respond

por Simpson, Mindy L., Desai, Vidhi, Maro, Géraldine S., Yan, Songkai
Publicado 2020

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients

por Yan, Songkai, Maro, Géraldine S., Desai, Vidhi, Simpson, Mindy L.
Publicado 2020

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

por Lalezari, Shadan, Acquadro, Michaël, de Bock, Elodie, Lambert, Jérémy, Simpson, Mindy L.
Publicado 2020

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

por Mancuso, Maria Elisa, Reding, Mark T., Negrier, Claude, Kerlin, Bryce A., Rangarajan, Savita, Simpson, Mindy L.
Publicado 2021

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study

por Simpson, Mindy L, Kulkarni, Roshni, Escuriola Ettingshausen, Carmen, Medom Meldgaard, Rikke, Cooper, David L, Klamroth, Robert
Publicado 2019

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

por Escuriola Ettingshausen, Carmen, Hegemann, Inga, Simpson, Mindy L., Cuker, Adam, Kulkarni, Roshni, Pruthi, Rajiv K., Garly, May‐Lill, Meldgaard, Rikke M., Persson, Paula, Klamroth, Robert
Publicado 2019